Doctor Concetta Crivera
Janssen Scientific Affairs, LLC, Raritan, NJ (United States of America)
Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy
Event: ESC Congress 2016
Topic: Thrombosis and coagulation
Session: Antithrombotics in daily clinical practice
ESC 365 is supported by
